Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL)
Sponsor: Ruijin Hospital
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, as well as preliminary efficacy of mRNA encoding CD19/CD3 T cell engager (ABO2203) in adult patients with relapsed or refractory CD19-positive B-NHL, This study included dose escalation and dose expansion parts.
Official title: A Clinical Study to Investigate Safety, Tolerability, and Preliminary Efficacy of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Adult Patients With Relapsed or Refractory B-NHL
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
56
Start Date
2025-05-26
Completion Date
2027-05
Last Updated
2025-07-18
Healthy Volunteers
No
Conditions
Interventions
ABO2203 Injection
SC or IV
Locations (1)
Ruijin Hospital
Shanghai, Shanghai Municipality, China